Last reviewed · How we verify
NCT05764174: DIAMOND-R
Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance
NA trial testing Factual messages in Vaccination Refusal in 2,409 participants. Completed in 17 December 2022.
17 December 2022
Quick facts
| Lead sponsor | Johns Hopkins Bloomberg School of Public Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 2,409 |
| Start date | 21 September 2022 |
| Primary completion | 17 December 2022 |
| Estimated completion | 17 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Factual messages
- Narrative message
- Mixed message
Conditions studied
- Vaccination Refusal — all drugs for Vaccination Refusal →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Johns Hopkins Bloomberg School of Public Health
Who can join
18 and older, any sex, with Vaccination Refusal or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Brief Summary: The main objective of this activity is to assess the effectiveness of different messaging strategies (factual, narrative, mixed and a control) to promote COVID-19 adult vaccination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05764174
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vaccination Refusal
Currently open trials in the same condition.
- NCT04779827 — Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks · NA · active not recruiting
Other Johns Hopkins Bloomberg School of Public Health trials
Trials by the same sponsor.
- NCT07458230 — Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation: · Phase 3 · not yet recruiting
- NCT07227558 — Improving Information Sharing Between Family Caregivers and Home Care Aides · NA · recruiting
- NCT07536126 — Testing Non-Nutrition Menu Labels on Food Selections · NA · not yet recruiting
- NCT06426004 — Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland · NA · not yet recruiting
- NCT07344142 — Improving Digital Wellbeing in Saudi Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05764174 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins Bloomberg School of Public Health
- Last refreshed: 10 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05764174.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing